Order Research Peptides in Japan — 99%+ Purity COA | Regena

Sourcing research peptides in Japan has historically meant choosing between under-documented offshore suppliers, opaque domestic re-sellers and compounding pharmacies pricing well above research-budget tolerances. Regena replaces all three with a verified-batch supply chain operated from inside the European Union: every vial ships with an independent third-party HPLC and mass-spectrometry COA, tracked tracked 5–14 day courier service across JP, and a research-use declaration that satisfies customs handling on entry.

For JP laboratories the practical effect is shorter project timelines and cleaner experimental risk. A batch ordered Monday is typically on the bench within the week, with the COA already cross-referenced against the vial cap batch number. There is no compounding-pharmacy markup, no anonymous reseller in the middle of the chain, and no week-long wait for analytical paperwork after dispatch.

The full Regena catalogue is available for Japan delivery — GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide), growth-hormone secretagogues (CJC-1295, ipamorelin, tesamorelin, MK-677 reference material), regenerative compounds (BPC-157, TB-500, GHK-Cu, KPV), mitochondrial peptides (MOTS-c, SS-31) and the wider research catalogue. Vials are 2 mg, 5 mg, 10 mg and 15 mg formats depending on the compound.

Every JP shipment includes the printed COA, batch number, lot number and compound-specific reconstitution guidance. Bacteriostatic water, sterile water, mixing vials and insulin syringes can be added to the same order so a JP bench has everything it needs for a complete reconstitution workflow on arrival.

JP orders ship tracked from our European hub with a standard transit window of 5–14 day. Dispatched from our European, US or Asian fulfilment hub with a research-use customs declaration and full batch paperwork; any local import duty or tax is calculated on entry to Japan. Vials travel in temperature-buffered mailers sized for the JP transit window so lyophilised product arrives within specification; refrigerate at 2–8 °C on arrival.

Express courier options are available through the consultations team for JP laboratories on tight project timelines. Delivery covers all of Japan including Tokyo, Osaka, Kyoto, Yokohama, Nagoya, Fukuoka and the broader Japanese research community. Residential, co-working and registered research-entity addresses are all accepted.

Regena peptides are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Japan, and are not dispensed against a prescription. Japan research-use peptide supply sits outside the PMDA-licensed medicinal-product regulation; nothing on the Regena catalogue is authorised by the PMDA for human use. The research-use declaration ships with every JP package and is sufficient for the courier and any internal procurement record.

JP researchers should ensure their work complies with the relevant institutional ethics framework and any local research-material handling rules. The Regena consultations team can pre-clear documentation questions before any vial is dispatched.

Every batch shipped to Japan ties back to an independent third-party COA hosted on the Regena lab reports page. Janoshik Analytical is the default verifier — the most widely cited independent peptide laboratory in Europe — with orthogonal laboratories used when batch chemistry calls for confirmation by a second method or when a JP institution requires a specific accredited laboratory.

Minimum specification for release is ≥99.0% HPLC main peak with matching mass-spectrometry molecular weight and water content within the published specification for the compound. Batches that do not meet the specification are not released, regardless of supply pressure on the JP channel.

Japan runs one of the world's deepest peptide-chemistry and biomedical research ecosystems, anchored in RIKEN, the University of Tokyo, Kyoto University and the Osaka University Institute for Protein Research, and Regena's batch documentation slots directly into JP institutional procurement and ethics workflows.

For multi-batch JP programmes — longitudinal stability studies, comparator panels, multi-cohort protocols — the consultations team will reserve inventory against a project timeline so an institutional buyer is not exposed to the wider catalogue's shifting availability. Material Safety Data Sheets, Certificates of Origin and Certificates of Conformity are supplied on request before dispatch.

Lyophilised peptides delivered to Japan should be held at 2–8 °C on arrival; long-term storage at −20 °C is appropriate for batches that will not be reconstituted within 8–12 months. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a two-month (60-day) in-use stability window under refrigeration for most analogues — single-day work can use sterile water but should not be saved for repeat use.

Aliquot before any freeze. The single most common cause of measurable potency loss in long-acting analogues — semaglutide, tirzepatide, retatrutide — is repeat freeze-thaw cycling. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers compound-specific stability windows for JP laboratories.

A free 20-minute consultation is available to every JP researcher. The call covers compound selection, batch availability, COA review, reconstitution workflow and any project-specific stability or sourcing questions. The Regena scientific team handles consultations directly — there is no sales tier between a JP laboratory and the people who release the batch.

Book through the /consultations page; the team responds within one working day. For urgent JP requests, the same channel handles express dispatch quotes, inventory reservations and bespoke documentation requests.